AR036154A1 - SPECIFIC ANTIBODIES OF CD44V6. - Google Patents
SPECIFIC ANTIBODIES OF CD44V6.Info
- Publication number
- AR036154A1 AR036154A1 ARP020101830A ARP020101830A AR036154A1 AR 036154 A1 AR036154 A1 AR 036154A1 AR P020101830 A ARP020101830 A AR P020101830A AR P020101830 A ARP020101830 A AR P020101830A AR 036154 A1 AR036154 A1 AR 036154A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- variants
- seq
- fragments
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Suspension/Interruption
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Anticuerpos con una secuencia especificada, que son específicos de un epítopo que está codificado por el exón v6 variante del gen CD44 y a derivados de dicho anticuerpo. También proporciona moléculas de ácido nucleico que codifican dichas proteínas anticuerpo. Además concierne a métodos para producir dichas proteínas anticuerpo. También proporciona composiciones farmacéuticas que comprenden dichas proteínas anticuerpo. Además está relacionado con la aplicación en la fabricación de un medicamento para el tratamiento del cáncer. Reivindicación 1: Una molécula de anticuerpo que comprende una región variable de la cadena pesada caracterizada por la secuencia de aminoácidos definida en la SEQ ID No. 1, o uno de sus fragmentos, variantes alélicas, variantes funcionales, variantes de glicosilación, moléculas de fusión o derivados químicos. Reivindicación 3: Una molécula de anticuerpo que comprende una región variable de la cadena ligera caracterizada por la secuencia de aminoácidos definida en la SEQ ID No. 2, o uno de sus fragmentos, variantes alélicas, variantes funcionales, variantes de glicosilación, moléculas de fusión o derivados químicos. Reivindicación 39: La proteína anticuerpo de la reivindicación 38, en la que dicho agente terapéutico es un agente terapéutico seleccionado entre el grupo constituido por radioisótopos, toxinas, toxoides, agentes inflamatorios y agentes quimioterapéuticos.Antibodies with a specified sequence, which are specific to an epitope that is encoded by exon v6 variant of the CD44 gene and derivatives of said antibody. It also provides nucleic acid molecules that encode said antibody proteins. It also concerns methods for producing said antibody proteins. It also provides pharmaceutical compositions comprising said antibody proteins. It is also related to the application in the manufacture of a drug for the treatment of cancer. Claim 1: An antibody molecule comprising a heavy chain variable region characterized by the amino acid sequence defined in SEQ ID No. 1, or one of its fragments, allelic variants, functional variants, glycosylation variants, fusion molecules or chemical derivatives. Claim 3: An antibody molecule comprising a variable region of the light chain characterized by the amino acid sequence defined in SEQ ID No. 2, or one of its fragments, allelic variants, functional variants, glycosylation variants, fusion molecules or chemical derivatives. Claim 39: The antibody protein of claim 38, wherein said therapeutic agent is a therapeutic agent selected from the group consisting of radioisotopes, toxins, toxoids, inflammatory agents and chemotherapeutic agents.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01112237 | 2001-05-18 | ||
| US32514701P | 2001-09-26 | 2001-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036154A1 true AR036154A1 (en) | 2004-08-18 |
Family
ID=33442672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101830A Suspension/Interruption AR036154A1 (en) | 2001-05-18 | 2002-05-17 | SPECIFIC ANTIBODIES OF CD44V6. |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1397387A1 (en) |
| JP (1) | JP2005504517A (en) |
| CN (1) | CN1541226A (en) |
| AR (1) | AR036154A1 (en) |
| BR (1) | BR0210905A (en) |
| CA (1) | CA2443437A1 (en) |
| CZ (1) | CZ20033476A3 (en) |
| EA (1) | EA200301169A1 (en) |
| EC (1) | ECSP034838A (en) |
| EE (1) | EE200300569A (en) |
| HU (1) | HUP0400030A3 (en) |
| MX (1) | MXPA03010523A (en) |
| PE (1) | PE20021098A1 (en) |
| PL (1) | PL365735A1 (en) |
| SK (1) | SK15592003A3 (en) |
| WO (1) | WO2002094879A1 (en) |
| YU (1) | YU91403A (en) |
| ZA (1) | ZA200307365B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8048416B2 (en) | 1999-10-08 | 2011-11-01 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US20050100542A1 (en) | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7947496B2 (en) | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7189397B2 (en) | 1999-10-08 | 2007-03-13 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US8071072B2 (en) | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| EP3101034A1 (en) | 2004-02-12 | 2016-12-07 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| ES2429340T3 (en) | 2005-03-10 | 2013-11-14 | Morphotek, Inc. | Anti-mesothelin antibodies |
| EP1879922A2 (en) | 2005-04-22 | 2008-01-23 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| CA2690119A1 (en) * | 2007-06-13 | 2008-12-24 | Ares Trading S.A. | Use of taci-ig fusion protein such as atacicep for the manufacture of a medicament for treating lupus erythematosus |
| EP2009028A1 (en) * | 2007-06-27 | 2008-12-31 | Monoclonal Antibodies Therapeutics | Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors |
| CA2786337A1 (en) | 2010-02-04 | 2011-08-11 | F. Hoffmann-La Roche Ag | A monoclonal antibody to cd44 for use in the treatment of head and neck squamous cell carcinoma |
| CN102337298B (en) * | 2011-08-19 | 2013-11-06 | 黄开红 | Immune nano-carrier for conveying siRNA (small interfering Ribonucleic Acid) and preparation method and application thereof |
| EP2788024A1 (en) | 2011-12-06 | 2014-10-15 | F.Hoffmann-La Roche Ag | Antibody formulation |
| WO2017215637A1 (en) * | 2016-06-15 | 2017-12-21 | 李翀 | Human endometrial cancer marker, antibody, and application of antibody |
| CN107556388A (en) * | 2016-06-30 | 2018-01-09 | 中国科学院深圳先进技术研究院 | The double targeting antibodies of anti-CD44v6 and CD3 specificity, the minicircle dna containing this pair of targeting antibodies expression cassette and application |
| WO2022187591A1 (en) * | 2021-03-05 | 2022-09-09 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP0438310A1 (en) * | 1990-01-19 | 1991-07-24 | Merck & Co. Inc. | Method for producing recombinant immunoglobuline |
| GB9020282D0 (en) * | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
| WO1994012631A1 (en) * | 1992-11-20 | 1994-06-09 | Isis Innovation Limited | Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors |
| UA58482C2 (en) * | 1994-06-08 | 2003-08-15 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | MONOCLONAL ANTIBODY VFF-18 AGAINST CD44v6 AND ITS FRAGMENTS |
| UY24389A1 (en) * | 1995-12-06 | 2001-10-25 | Karlsruhe Forschzent | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FLAT EPITHELIUM CARCINOMA |
-
2002
- 2002-05-17 SK SK1559-2003A patent/SK15592003A3/en not_active Application Discontinuation
- 2002-05-17 EE EEP200300569A patent/EE200300569A/en unknown
- 2002-05-17 EP EP02735364A patent/EP1397387A1/en not_active Ceased
- 2002-05-17 CZ CZ20033476A patent/CZ20033476A3/en unknown
- 2002-05-17 CA CA002443437A patent/CA2443437A1/en not_active Abandoned
- 2002-05-17 AR ARP020101830A patent/AR036154A1/en not_active Suspension/Interruption
- 2002-05-17 PL PL02365735A patent/PL365735A1/en not_active Application Discontinuation
- 2002-05-17 YU YU91403A patent/YU91403A/en unknown
- 2002-05-17 HU HU0400030A patent/HUP0400030A3/en unknown
- 2002-05-17 PE PE2002000422A patent/PE20021098A1/en not_active Application Discontinuation
- 2002-05-17 MX MXPA03010523A patent/MXPA03010523A/en unknown
- 2002-05-17 EA EA200301169A patent/EA200301169A1/en unknown
- 2002-05-17 WO PCT/EP2002/005467 patent/WO2002094879A1/en not_active Application Discontinuation
- 2002-05-17 CN CNA028101561A patent/CN1541226A/en active Pending
- 2002-05-17 JP JP2002592353A patent/JP2005504517A/en active Pending
- 2002-05-17 BR BR0210905-0A patent/BR0210905A/en not_active Expired - Fee Related
-
2003
- 2003-09-22 ZA ZA200307365A patent/ZA200307365B/en unknown
- 2003-11-10 EC EC2003004838A patent/ECSP034838A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| YU91403A (en) | 2006-05-25 |
| JP2005504517A (en) | 2005-02-17 |
| ZA200307365B (en) | 2004-05-10 |
| HUP0400030A3 (en) | 2006-02-28 |
| EP1397387A1 (en) | 2004-03-17 |
| CN1541226A (en) | 2004-10-27 |
| MXPA03010523A (en) | 2004-07-01 |
| BR0210905A (en) | 2004-06-08 |
| HUP0400030A2 (en) | 2004-04-28 |
| EE200300569A (en) | 2004-04-15 |
| WO2002094879A1 (en) | 2002-11-28 |
| EA200301169A1 (en) | 2004-06-24 |
| SK15592003A3 (en) | 2004-06-08 |
| PE20021098A1 (en) | 2003-02-11 |
| PL365735A1 (en) | 2005-01-10 |
| ECSP034838A (en) | 2003-12-24 |
| CZ20033476A3 (en) | 2004-05-12 |
| CA2443437A1 (en) | 2002-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036154A1 (en) | SPECIFIC ANTIBODIES OF CD44V6. | |
| PE20050376A1 (en) | ANTIBODIES TARGETING M-CSF | |
| ECSP044978A (en) | HUMAN ANTIBODIES ANTAGONISTS AGAINST hTNFSF13b | |
| ECSP14011269A (en) | HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS | |
| ATE510011T1 (en) | NEW FUNGAL PROTEINS AND THE NUCLEIC ACIDS THAT ENCOD THEM | |
| AR047717A1 (en) | ANTIBODIES DIRECTED TO C-MET | |
| EA200801509A1 (en) | HUMAN MONOCLONAL ANTIBODIES TO PROTEINTHYROSINKINASE 7 (PTK7) AND METHODS OF APPLICATION OF ANTIBODIES AGAINST PTK7 | |
| DE60224291D1 (en) | SYSTEM FOR ANTIBODY EXPRESSION AND SYNTHESIS | |
| AR045056A1 (en) | ANTI-NGF ANTIBODIES NEUTRALIZING HUMANS AS SELECTIVE INHIBITORS OF THE NGF ROAD | |
| AR086272A2 (en) | ANTI-FACTOR D HUMANIZED ANTIBODIES AND THEIR USES | |
| BRPI0411112A (en) | heterologous fusion protein, polynucleotide, vector, host cell, process for producing a heterologous fusion protein, method for treating a patient, and use of heterologous fusion protein | |
| AR001778A1 (en) | Monoclonal antibody antiintegrins alpha-v hybridoma cell line that produces this antibody DNA sequences that encode for this antibody pharmaceutical composition based on the antibody and a method to produce said antibody | |
| UA87804C2 (en) | Human monoclonal antibody that specifically binds to insulin-like growth factor i receptor (igf-ir) | |
| CY1112334T1 (en) | Homologous IL-17 Polypeptides and their therapeutic uses | |
| SG170080A1 (en) | Human monoclonal antibodies to o8e | |
| AR030236A1 (en) | MOLECULES SIMILAR TO IL-17 AND USES OF THE SAME | |
| TW200635946A (en) | Binding proteins specific for human matriptase | |
| NO20053304L (en) | NOGO A binding molecules and their pharmaceutical use | |
| EA200701947A1 (en) | EASY PHARMACEUTICAL WATER, THERAPEUTIC COMPOSITIONS, ITS CONTAINING, METHODS OF THEIR PRODUCTION AND APPLICATION | |
| JP2005504517A5 (en) | ||
| AR050561A1 (en) | PLASMINOGEN ACTIVATING FUSION PROTEINS AS THROMBOLITIC AGENTS. | |
| BRPI0407031A (en) | Compositions and methods for cancer treatment using igsf9 and liv-1 | |
| EA200600042A1 (en) | METHODS OF FORMATION OF DISULFIDIC LINKS AND GLYCOSYLATION OF PROTEINS AND REAGENTS USED IN THESE METHODS | |
| EP0369816A3 (en) | Monoclonal antibodies specific for human polymorphic epithelial mucin | |
| AR004360A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE THERAPY OF CARCINOMAS OF THE FLAT EPITHELIUM AND AN AGENT TO BE EMPLOYED IN THESE PHARMACEUTICAL COMPOSITIONS. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |